Hristov · Cureus 2022 · narrative review · n=?

The Role of Glutathione Metabolism in Chronic Illness Development and Its Potential Use as a Novel Therapeutic Target.

Level 5 - mechanism / opinion, no new human data

Narrative review synthesizing mechanistic concepts, proxy observational markers, and preliminary trials without systematic review methods

PubMed 36321012 · doi:10.7759/cureus.29696 · record verified 2026-08-26

What was done

This narrative review synthesized literature evaluating whether low glutathione (GSH) levels contribute to chronic pro-inflammatory diseases, such as metabolic syndrome, cardiovascular, hepatic, renal, and neurodegenerative conditions. Because large prospective human trials measuring GSH directly are lacking, the authors examined prospective studies tracking gamma-glutamyl transferase (GGT) as a surrogate biomarker, alongside preliminary animal and human trials of GSH precursor supplementation.

What was found

The abstract reports no numerical data, confidence intervals, or specific effect sizes. It qualitatively notes that prospective studies demonstrate a dose-dependent correlation between elevated GGT levels and the risk of developing metabolic syndrome and cardiovascular disease. It also reports that preliminary human and animal trials show improved outcomes across chronic conditions following GSH augmentation.

Why it matters

This review outlines the conceptual framework for viewing glutathione depletion as a common pathological thread in chronic cardiometabolic and degenerative diseases, proposing GGT screening and precursor supplementation as potential low-cost primary care strategies.

Limits

The review is narrative and non-systematic, lacking defined search criteria and quantitative synthesis. It relies heavily on GGT as an indirect proxy for systemic GSH status. Furthermore, the underlying intervention studies reviewed are described as small and preliminary, offering insufficient evidence to establish clinical efficacy or standardized dosing.

Cited by